



NIH AIDS Reagent Program

20301 Century Boulevard
Building 6, Suite 200
Germantown, MD 20874
USA

Phone: 240 686 4740
Fax: 301 515 4015
aidsreagent.org

DATA SHEET

Reagent: Anti-HIV-1 gp120 Monoclonal (5F7)

Catalog Number: 2533

Lot Number: 011636

Release Category: D

Provided: 1 ml tissue culture supernatant.

Host: Balb/c splenocyte x Ag8658 myeloma.

Special Characteristics: Raised against hybrid HBcAg/HIV-1 gp120 (aa 303-327) particles. Recognizes LAI gp160 and the V3 peptide RIQRGPGRAFVTGK (aa 308-322) in ELISA. Reacts in Western blots with gp120 (LAI) and in IFA of HIV-1_{LAI}-infected H9 cells. The antibody inhibits syncytium formation, RT activity, and p24 production *in vitro* (partial inhibition and retardation over 20 days).

[Image I](#)

Recommended Storage: Keep at 4°C for short term storage and -80°C for long term storage. Avoid freeze-thaw cycles as reagent degradation may result.

Contributor: Dr. Albrecht von Brunn, Courtesy of the MRC AIDS Directed Programme.

Isotype: IgG₁.

References: von Brunn A, Brand M, Reichhuber C, Morys-Wortman C, Deinhardt F, Schödel F. Principal neutralizing domain of HIV-1 is highly immunogenic when expressed on the surface of hepatitis B core particles. *Vaccine* **11**:817-824, 1993.

von Brunn A, Reichhuber C, Brand M, Bechowsky B, Gürtler L, Eberle J, Kleinschmidt A, Erfle V, Schödel F. The principal neutralizing determinant (V3) of HIV-1 induces HIV-1-neutralizing antibodies upon expression on HBcAg particles. In: *Vaccines 93*, Cold Spring Harbor Press; Cold Spring Harbor, New York, pp 159-165, 1993.

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

NOTE:

Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: Anti-HIV-1 gp120 Monoclonal (5F7) from Dr. Albrecht von Brunn, Courtesy of the MRC AIDS Directed Programme." Also include the references cited above in any publications.

Last Updated

December 08, 2017

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.